Stenotrophomonas maltophilia Infection Associated with COVID-19: A Case Series and Literature Review

Kazuhiro Ishikawa
Tomoaki Nakamura
Fujimi Kawai
Yuki Uehara
Nobuyoshi Mori

Corresponding Author: Kazuhiro Ishikawa, e-mail: isikawakazuhiro@gmail.com

Financial support: None declared
Conflict of interest: None declared

Case series
Patients: Female, 52-year-old • Male, 80-year-old • Male, 48-year-old • Male, 80-year-old
Final Diagnosis: COVID pneumonia
Symptoms: Cough
Medication: —
Clinical Procedure: —
Specialty: Infectious Diseases

Objective: Rare disease
Background: We aimed to identify the risk factors for Stenotrophomonas maltophilia infection in patients with COVID-19.

Case Reports:
Case 1. A 52-year-old COVID-19-positive woman with systemic lupus erythematosus was administered remdesivir (RDV) and methylprednisolone (mPSL) 1000 mg/day for 3 days, and subsequently administered baricitinib and ceftriaxone. Following respiratory deterioration, she was transferred to the Intensive Care Unit (ICU) and the antibiotics were switched to meropenem (MEPM). Blood and sputum cultures were positive for S. maltophilia. Administration of trimethoprim-sulfamethoxazole (TMP-SMX) showed clinical improvement.

Case 2. An 80-year-old COVID-19-positive man was treated with RDV, dexamethasone, and baricitinib. Owing to severe hypoxia, he was transferred to the ICU and MEPM was administered. Sputum culture was positive for S. maltophilia. TMP-SMX administration temporarily improved his symptoms; however, he died from COVID-19-associated invasive aspergillosis.

Case 3. A 48-year-old COVID-19-positive man who was mechanically intubated was transferred to our hospital and treated with RDV, mPSL, and piperacillin/tazobactam. Sputum culture revealed S. maltophilia; treatment with TMP-SMX improved his respiratory status.

Case 4. An 80-year-old COVID-19-positive man was treated with RDV and dexamethasone. Owing to severe hypoxemia, he was transferred to the ICU and the antibiotics were switched to MEPM. Sputum culture revealed S. maltophilia. Administration of TMX-SMX improved his respiratory status.

Conclusions: Isolation of S. maltophilia in respiratory specimens of patients with COVID-19 should prompt clinicians to administer treatment for S. maltophilia-associated pneumonia in ICU-admitted patients who have been intubated, have been administered broad-spectrum antibiotics, or have immunocompromised status.

Keywords: Stenotrophomonas maltophilia • Stenotrophomonas maltophilia Bacteremia • COVID-19 Breakthrough Infections • Healthcare-Associated Pneumonia

Full-text PDF: https://www.amjcaserep.com/abstract/index/idArt/936889
Background

*Stenotrophomonas maltophilia*, a multidrug resistant, gram-negative bacterial rod is found in aquatic environments, such as water, soil, and plants. Owing to its ability to form biofilms on medical equipment and to grow in disinfectants, it is an emerging opportunistic pathogen known to cause bacteremia, pneumonia, endocarditis, and meningitis, as well as urinary tract, ocular, bone and joint, skin and soft tissue, and gastrointestinal infections in hospitals settings [1]. *S. maltophilia* infections include ventilator-associated pneumonia (VAP) and central venous catheter (CVC)-related bacteremia [2]. *S. maltophilia* bacteremia has a mortality rate of over 20%, and risk factors include Intensive Care Unit (ICU) admission, indwelling devices such as CVC and ventilators, exposure to carbapenems and anti-*Pseudomonas aeruginosa* cephalosporins within 14 days prior to bacteremia, and *S. maltophilia* isolation within 30 days [3]. *S. maltophilia* pneumonia has been reported to cause opportunistic infections in some patients, such as those with hematologic malignancy [4]. *S. maltophilia* colonizes the sputum, and a high sequential organ failure assessment score is seen in patients who are immunocompromised and exposed to broad-spectrum antimicrobial agents [5]. It is difficult to determine whether *S. maltophilia* simply colonizes the lungs or causes true infection leading to pulmonary inflammation. Despite a few reports of *S. maltophilia* pneumonia in patients with COVID-19, the risk factors for *S. maltophilia* infection in COVID-19-positive patients are unknown. Herein, we aimed at identifying the risk factors for *S. maltophilia* infection in patients with COVID-19 based on the information available in the literature and on our cases in St Luke’s International Hospital between January 1, 2020, and August 31, 2021.

Case Reports

This study was approved by the Institutional Review Board of St. Luke’s International Hospital in Tokyo, Japan (No: 21-R107). Although written informed consent was obtained from all patients in this case series, the requirement for patient consent was waived by the Institutional Review Board due to the study’s retrospective nature.

Case 1

A 52-year-old woman using prednisolone (PSL) and baricitinib (BARI) with a medical history of systemic lupus erythematosus,
Figure 2. Mucoid-type S. maltophilia colony. String-positive (A), S. maltophilia on blood agar (B).

Figure 3. Clinical course of Case 1. RDV – remdesivir; ICU – Intensive Care Unit; mPSL – methylprednisolone; CTRX – ceftriaxone; MEPM – meropenem; TMP-SMX – trimethoprim-sulfamethoxazole; VRCZ – voriconazole; BT – body temperature; P/F – PaO₂/FIO₂; BARI – baricitinib.
rheumatoid arthritis, liver cirrhosis, and interstitial pneumonia was admitted to our Emergency Department with high fever and headache. On admission, her vital signs were as follows: clear consciousness; temperature, 37.2°C; blood pressure, 101/77 mmHg; pulse rate, 100 beats/min; respiratory rate, 22 breaths/min; and oxygen saturation, 94% on room air. The patient’s COVID-19 polymerase chain reaction (PCR) test result was positive. Chest computed tomography (CT) revealed bilateral, non-segmental, ground-glass opacities in the diffuse area, and honeycomb appearance associated with interstitial pneumonia in the bilateral dorsal aspects of the inferior lung lobe (Figure 1A-1C). We initiated administration of remdesivir (RDV) and methylprednisolone (mPSL) 1000 mg/day for 3 days followed by mPSL 40 mg/day, BARI 4 mg/day, and ceftriaxone (CTRX) 1 g intravenously (i.v.) every 24 h. On day 4 of hospital admission, her respiratory status worsened, she was moved to the ICU, and a nasal high flow cannula was inserted. We switched the antibiotics to meropenem (MEPM). On day 8, the patient developed a fever of 37.9°C with 90% oxygen saturation with FIO₂ 60% and nasal high flow gas 40 L/min, and was intubated. Blood and sputum cultures were positive for \textit{S. maltophilia} (Figure 2A, 2B). Mucoid-type \textit{S. maltophilia} was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Biotyper, Bruker Daltonics, Germany). Adjustment to 0.5 McFarland in the mucoid-type \textit{S. maltophilia} was difficult; thus, susceptibility testing could not be performed. Intravenous trimethoprim-sulfamethoxazole (TMP-SMX) (equivalent to 15 mg/kg/day TMP) was initiated. Her respiratory status improved; however, the \textit{Aspergillus} galactomannan antigen level was 1.1. We administered voriconazole to treat COVID-19-associated invasive aspergillosis. The patient’s respiratory condition stabilized, although the duration of intubation was extended; consequently, tracheostomy was performed. Sputum culture revealed elimination of \textit{S. maltophilia}. At the time of writing this review, the patient’s clinical status had improved (Figure 3).

### Case 2
An 80-year-old man with a medical history of hypertension and acute myocardial infarction status after coronary artery bypass graft was admitted to our Emergency Department with high fever. On admission, the vital signs were as follows: clear consciousness; temperature, 37.6°C; blood pressure, 101/77 mmHg; pulse rate, 98 beats/min; respiratory rate, 22 breaths/min; and oxygen saturation, 96% (10 L/min on reservoir mask). The patient’s COVID-19 PCR result was positive. Chest CT revealed...
bilateral ground-glass opacity and reticulation with subpleural distribution (Figure 4A, 4B). We initiated administration of RDV, dexamethasone (DEXA) 6.6 mg/day, BARI 4 mg/day, and CTRX 1 g i.v. every 24 h. Owing to severe hypoxemia, he was transferred to the ICU and mechanically intubated, and a CVC was inserted. On day 4 of hospital admission, he developed a fever of 38°C, and antibiotics were switched to piperacillin/tazobactam (PIPC/TAZ). A sputum culture on day 8 revealed the presence of Candida glabrata (mold) and S. maltophilia; however, we did not administer any treatment for these as we assumed them to be colonizing organisms. The minimum inhibitory concentrations were measured using the MicroScan WalkAway 96 Plus and NC-NF2J panel (Beckman Coulter Inc). Levofloxacin (LVFX), minocycline (MINO), TMP-SMX, and ceftazidime were all effective (Table 1). The patient had persistent prominent fever; however, and a blood culture on day 11 indicated C. glabrata infection. We administered micafungin and replaced the CVC. Follow-up blood cultures were negative for C. glabrata; however, the fever did not abate, and on day 18 the patient showed increased hypoxia. Switching antibiotics from PIPC/TAZ to MEPM did not improve the clinical symptoms. Therefore, we administered TMP-SMX (equivalent to 15 mg/kg/day TMP) for treating S. maltophilia-associated pneumonia, and the fever resolved. Owing to acute kidney injury, we switched from TMP-SMX to LVFX and MINO. Aspergillus galactomannan sputum antigen was >5.0, and we administered voriconazole. However, the patient’s respiratory status worsened. He died on day 28 of hospital admission due to COVID-19-associated invasive aspergillosis (Figure 5).

**Case 3**
A 48-year-old man with COVID-19 and a medical history of hypertension, diabetes, and obesity was admitted to another hospital, where he was treated with RDV and DEXA. His respiratory condition deteriorated, and he was mechanically intubated and treated with mPSL 1000 mg/day for 3 days. On day 7 following COVID-19 onset, his PaO/FiO ratio was about 80. He was transferred to our hospital for COVID-19 treatment with extracorporeal membrane oxygenation (ECMO). Chest CT revealed bilateral diffuse consolidation (Figure 6). He was treated with RDV, mPSL 125 mg/day, and PIPC/TAZ. His respiratory
status stabilized; therefore, ECMO was discontinued, and he was extubated on day 9. On day 10 of hospital admission, he had increased sputum production and his C-reactive protein level increased to 23.7 mg/dL. Chest radiography revealed consolidation in the right lower lung field (Figure 6). The sputum culture revealed the presence of *S. maltophilia*; therefore, he was treated with TMP-SMX (equivalent to 15 mg/kg/day TMP). By the time of this report, the patient was clinically stable and preparing for transfer to a rehabilitation hospital (Figure 7).

**Case 4**

An 80-year-old man with a medical history of dementia developed COVID-19 four days before admission. The patient was medically monitored at a health care institute. When his O₂ saturation level gradually decreased, he was admitted to our hospital. Chest CT revealed ground-glass opacity with subpleural distribution (Figure 8). We started RDV, DEXA 6.6 mg/day, AZM 500 mg/day, and CTRX 1 g i.v. every 24 h. Owing to severe hypoxemia, he was transferred to the ICU and mechanically intubated on day 6 after hospital admission. On day 9, his sputum culture revealed *S. maltophilia*, *Klebsiella aerogenes*, and *Enterococcus faecalis*. Although susceptible to LVFX, MINO, and TMP-SMX, the bacteria were resistant to ceftazidime (Table 2). The patient was treated with LVFX 500 mg/day. On day 18 of hospital admission, he was extubated. However, his sputum production increased, and he was re-intubated on day 34. He was treated with TMP-SMX (equivalent to 15 mg/kg/day TMP) and MEPM. His respiratory status improved, although a tracheostomy had to be performed because of CO₂ retention. He was finally transferred to a rehabilitation hospital on day 56 of hospital admission (Figure 9).
Discussion

Two authors independently reviewed the relevant titles and abstracts in the database records, retrieved full texts for eligibility assessment, and extracted the information from these cases. We performed a search using the keywords “Stenotrophomonas maltophilia” and “COVID-19” in the electronic databases PubMed, Embase, and Ichushi from January 1, 2020, to April 4th, 2022 (Table 3).

We found 68 articles and 8 case reports on COVID-19-associated S. maltophilia infection (Figure 10). The clinical characteristics of the patients in the 8 published cases, including the 4 in this review, are shown in Table 4. Furthermore, we extracted 13 retrospective studies on COVID-19-associated S. maltophilia infections, which are shown in Table 5.

We extracted the data of 8 patients with COVID-19 and positive S. maltophilia cultures at St. Luke’s International Hospital, a 520-bed teaching hospital in Tokyo (Figure 10). Four patients were diagnosed with S. maltophilia colonization, while the other 4 had COVID-19-associated S. maltophilia infection (Table 4). The median age of the 12 patients, including the 4 patients in this review, with COVID-19-associated S. maltophilia infection was 64 years (Table 4). Among them, 10 (83%) were men. Eleven patients (92%) were admitted to the ICU, and 12 (100%) were mechanically intubated. Immunosuppressants such as steroids, BARI, and tocilizumab were used in 9 (75%) patients; however, only DEXA, a short-term steroid used for COVID-19, was administered in 2 patients. Antimicrobial agents were administered to almost all patients, including MEPM to 5 patients, PIPC/TAZ to 2 patients, and cefepime to 1 patient. The treatment against S. maltophilia was TMP-SMX in 7 patients, and 2 were switched from TMP-SMX to LVFX owing to acute renal injury; LVFX was used in 5 patients, including 2 patients who were switched from TMP-SMX, as mentioned above. There were 3 deaths. In our hospital, there were 4 patients with S.

Figure 7. Clinical course of Case 3. RDV – remdesivir; PIPC/TAZ – piperacillin/tazobactam; TMP-SMX – trimethoprim-sulfamethoxazole; ICU – Intensive Care Unit; ECMO – extracorporeal membrane oxygenation; NHF – nasal high flow; mPSL – methylprednisolone; DEX – dexamethasone; CRP – C-reactive protein; P/F = PaO₂/FIO₂.

Table 3. Relevance of titles and abstracts retrieved from PubMed, Embase, and Ichushi (n=68 articles + 8 case reports).

Table 4. Characteristics of 8 patients with COVID-19-associated S. maltophilia infection.

Table 5. Characteristics of 13 retrospective studies on COVID-19-associated S. maltophilia infections.
maltophilia colonization, all of whom were admitted to the ICU, 3 who were administered steroids, and 3 who were administered broad-spectrum antibiotics such as cefepime, PIPC/TAZ, or MEPM. Two patients had positive sputum cultures; however, they were resolved without treatment. Autopsy blood cultures from 2 patients were positive for \textit{S. maltophilia}, although their antemortem blood cultures were negative.

Among the 13 observational studies (Table 5), 4 were from China, 2 from Italy, 2 from Spain, and 5 from the United States. Nine of the 13 studies were conducted in the ICU (2 studies had mixed ICU and non-ICU patients). Eleven studies included respiratory infections, such as VAP and hospital-acquired

| Antibiotics | MIC (μg/mL) | Susceptibility |
|-------------|-------------|----------------|
| MINO        | ≤2          | S              |
| TMP-SMX     | ≤2          | S              |
| LVFX        | ≤0.5        | S              |
| CAZ         | >16         | R              |

MIC breakpoint reference: M100 in Clinical and Laboratory Standards Institute (CLSI). S – susceptible; MINO – minocycline; TMP-SMX – trimethoprim-sulfamethoxazole; LVFX – levofloxacin; CAZ – ceftazidime; MIC – minimum inhibitory concentration.
pneumonia (HAP). Mortality rates ranged from 15.4% to 52.4%, although we did not find any mortality rate for S. maltophilia-associated VAP or HAP. In addition to S. maltophilia, the organisms Acinetobacter spp., P. aeruginosa, and Enterobacter spp. were the causative or isolated organisms in VAP and HAP. Here, we report 4 cases of COVID-19-associated S. maltophilia infection. To the best of our knowledge, this is the first literature review on COVID-19-associated S. maltophilia infection. It may help clinicians make treatment choices by presenting clinical data on patient backgrounds, treatment choices, and outcomes of COVID-19-associated S. maltophilia infection, for which no consensus has been reached.

S. maltophilia can form small colony variants [6], and the one detected in Case 1 was considered to be of the mucoid type as it was a large, viscous colony with a positive string test. Reports of mucoid-type S. maltophilia are rare: only 1 case from Japan has been previously reported [7]. Further studies are needed to clarify the mechanism of mucoid-type S. maltophilia.

Among patients without COVID-19, the risk of S. maltophilia infection was higher in patients who were admitted to the ICU, intubated, and had exposure to broad-spectrum antimicrobials and used immunosuppressants [3,5]. In this review, patients with COVID-19 had similar risk factors for S. maltophilia infection. In our observational study at St Luke’s International Hospital, S. maltophilia colonization was 50% in 8 patients. It is difficult to distinguish between patients with S. maltophilia colonization and infection as they have similar baseline characteristics. The previous study reported that VAP caused by S. maltophilia is associated with high morbidity and mortality [6]. Another study reported a mortality rate due to S. maltophilia bacteremia ranging from 12.5% to 41% [7]. According to the Infectious Diseases Society of America guideline, the overall VAP mortality rate is 20% to 50% [8]. Therefore, the mortality rate for S. maltophilia is also high enough. Owing to the high mortality rate of COVID-19-associated S. maltophilia infection, we believe that this condition should be treated in clinically unstable patients. In general, S. maltophilia-associated pneumonia was diagnosed 11 days after intubation and 11 days after ICU admission [8]. In the present study, COVID-19-associated S. maltophilia was either isolated from the culture immediately after ICU admission or was positive in the PCR test for S. maltophilia if not detected in the culture [9,10]. Therefore, S. maltophilia infection should be considered immediately after ICU admission.
Table 3. Search terms used to search 3 databases (PubMed, Embase, and Ichushi) for literature review of COVID-19-associated Stenotrophomonas maltophilia.

| Database | Search Terms |
|----------|-------------|
| PubMed   | (“Stenotrophomonas maltophilia”[MeSH Terms] OR “Stenotrophomonas maltophilia”[Text Word] OR “Stenotrophomonas maltophilia bacteremia”[Supplementary Concept] OR “Pseudomonas maltophilia”[Title/Abstract] OR “Xanthomonas maltophilia”[Title/Abstract]) AND (“Pneumonia”[MeSH Terms] OR “pneumoni*”[Text Word] OR “pulmonary infect*”[Title/Abstract] OR “lung infect*”[Title/Abstract]) AND “Respiratory Tract Infections”[MeSH Terms] AND (“COVID-19”[All Fields] OR “COVID-19”[MeSH Terms] OR “COVID-19 Vaccines”[All Fields] OR “COVID-19 Vaccines”[MeSH Terms] OR “COVID-19 serotherapy”[All Fields] OR “COVID-19 serotherapy”[Supplementary Concept] OR “covid 19 nucleic acid testing”[All Fields] OR “covid 19 nucleic acid testing”[MeSH Terms] OR “covid 19 serological testing”[All Fields] OR “covid 19 serological testing”[MeSH Terms] OR “covid 19 testing”[All Fields] OR “covid 19 testing”[MeSH Terms] OR “sars cov 2”[All Fields] OR “sars cov 2”[MeSH Terms] OR “Severe Acute Respiratory Syndrome Coronavirus 2”[All Fields] OR “NCOV”[All Fields] OR “2019 NCOV”[All Fields] OR “coronavirus”[MeSH Terms] OR “coronavirus”[All Fields] OR “COV”[All Fields] AND 2019/11/01: 3000/12/31[Date – Publication]) AND (“Stenotrophomonas maltophilia” OR maltophilia) AND (pneumoni* OR (“pulmonary infect*” OR “lung infect*”) OR “respiratory tract infection”[exp]) |
| Embase   | (“severe acute respiratory syndrome coronavirus 2”[exp OR ‘2019-ncov’: ti,ab,kw OR ‘cov 2’: ti,ab,kw OR ‘sars cov 2’: ti,ab,kw OR ‘coronavirus 2’: ti,ab,kw OR ‘covid 19’: ti,ab,kw OR ‘2019 ncov’: ti,ab,kw OR ‘cov2’: ti,ab,kw OR ‘corona virus disease 2019’: ti,ab,kw OR ‘covid 19’: ti,ab,kw OR ‘covid-19’: ti,ab,kw OR ‘covid 2019’: ti,ab,kw OR ‘ncov’: ti,ab,kw OR ‘new corona virus’: ti,ab,kw OR ‘new coronaviruses’: ti,ab,kw OR ‘novel corona virus’: ti,ab,kw OR ‘novel coronaviruses’: ti,ab,kw OR ‘sars cov 2’: ti,ab,kw OR ‘sars cov 2’[MeSH Terms] OR ‘sars cov 2’: ti,ab,kw OR ‘sars2’: ti,ab,kw OR ‘sars-cov-2’: ti,ab,kw OR ‘severe acute respiratory syndrome coronavirus 2’: ti,ab,kw OR (‘19: ti,ab,kw OR ‘2019: ti,ab,kw OR ‘2019-ncov’: ti,ab,kw OR ‘beijing’: ti,ab,kw OR ‘china’: ti,ab,kw OR ‘covid-19’: ti,ab,kw OR ‘epidemi*’: ti,ab,kw OR ‘epidemic*’: ti,ab,kw OR ‘epidemic’: ti,ab,kw OR ‘new’: ti,ab,kw OR ‘novel’: ti,ab,kw OR ‘outbreak’: ti,ab,kw OR ‘pandem*’: ti,ab,kw OR ‘sars-cov-2’: ti,ab,kw OR ‘sars-cov-2’[MeSH Terms] OR ‘sars-cov-2’: ti,ab,kw OR ‘shanghai’: ti,ab,kw OR ‘wuhan’: ti,ab,kw) AND (‘coronavirinae’/exp OR ‘coronavirus infection’/exp OR ‘coronavirus’/exp) AND (‘covid 19 nucleic acid testing’/exp OR ‘covid 19 serological testing’/exp OR ‘covid 19 testing’/exp) AND (‘Stenotrophomonas maltophilia’ OR maltophilia) AND (pneumoni* OR ‘pulmonary infect*’ OR ‘lung infect*’) OR ‘respiratory tract infection’/exp) |
| Ichushi   | (SARS coronavirus[Japanese] OR COVID-19[TH] OR COVID-19[AL] OR (corona[Japanese]/TA and DT=2020:2021)) AND (“Stenotrophomonas maltophilia”/TH) OR (maltophilia[Japanese]/TA or maltophilia/TA) |

Figure 10. Flow chart of the systematic review process.
| No | Case reference | Age | Sex | Publisheddate/country | Diagnosis/ complications | Underlying diseases | Ward |
|----|----------------|-----|-----|------------------------|-------------------------|----------------------|------|
| 1  | Su XW [19]     | 72  | Male| 2020/USA               | S. maltophilia VAP/ Guillain-Barré syndrome | HTN, CAD, alcohol abuse | ICU  |
| 2  | Mohamed AM [20]| 64  | Male| 2020/USA               | S. maltophilia VAP       | DM, HTN, ESRD, post-renal transplant recipient taking TAC, MMF and PSL 5 mg/day | ICU  |
| 3  | Zachary P [21] | 60s | Male| 2021/USA               | S. maltophilia VAP, bacteremia/septic shock, MOF, myopericarditis | Asthma, hyperlipidemia, elevated BMI | N/A  |
| 4  | Vikas P [22]   | 55  | Male| 2021/USA               | S. maltophilia VAP/ARDS, pneumothorax | No                   | ICU  |
| 5  | Nicole N [23]  | 51  | Male| 2021/Lebanon           | S. maltophilia VAP, bacteremia/bacterial pneumonia | hemodialysis, Von Hippel-Lindau disease, renal cell carcinoma leading to bilateral nephrectomy and adrenalectomy, cystadenoma of the pancreas, DM, HTN, CAD | ICU  |
| 6  | Miraç Öz [24]  | 61  | Male| 2020/Turkey            | S. maltophilia VAP       | COPD, bronchiectasis, previous TB, bilateral upper lobectomies nearly 30 years ago. tracheostomy and had been ventilating with a home-type of mechanical ventilator for two years | ICU  |
| 7  | David D [25]   | 71  | Male| 2021/Iran              | S. maltophilia VAP       | Hodgkin’s lymphoma   | ICU  |
| 8  | Velamakanni S [26] | 70 | Female| 2021/USA             | S. maltophilia VAP       | HTN, PAD, COPD       | ICU  |
| 9  | Our case       | 52  | Female| 2021/Japan             | S. maltophilia VAP, bacteremia/CAPA | SLE, RA, IP, LC | ICU  |
| 10 | Our case       | 79  | Male| 2021/Japan             | S. maltophilia VAP       | dementia             | ICU  |
| 11 | Our case       | 80  | Male| 2021/Japan             | S. maltophilia VAP/CAPA, candidemia | HTN, post-CABG | ICU  |
| 12 | Our case       | 48  | Male| 2021/Japan             | S. maltophilia VAP       | Af, DM, HTN, obesity | ICU  |

Table 4. Literature review of COVID-19-associated Stenotrophomonas maltophilia + cases at our hospital.

Contamination
Table 4 continued. Literature review of COVID-19-associated *Stenotrophomonas maltophilia* + cases at our hospital.

| No  | Case reference | Age  | Sex | Published date/country | Diagnosis/complications | Underlying diseases | Ward |
|-----|----------------|------|-----|-------------------------|-------------------------|---------------------|------|
| 1   | Our case       | 64   | Male| 2020/ Japan             | Post-AVR, hyperlipidemia, Af | ICU                |
| 2   | Our case       | 85   | Female| 2020/ Japan         | Af, DM, distal radius fracture | ICU                |
| 3   | Our case       | 79   | Male| 2020/ Japan             | TB, DM, HTN, hyperlipidemia | ICU                |
| 4   | Our case       | 52   | Female| 2021/ Japan         | HTN                     | ICU                |

| No  | Case reference | Mechanical intubation | COVID-19 treatment | Antibiotics prior to *S. maltophilia* infection | Specimen | *S. maltophilia* treatment | Outcome | Other pathogen |
|-----|----------------|----------------------|--------------------|-----------------------------------------------|----------|--------------------------|---------|----------------|
| 1   | Su XW [19]     | Yes                  | N/A                | No                                           | Sputum   | TMP-SMX                  | Under treatment | N/A            |
| 2   | Mohamed AM [20]| Yes                  | HCQ, AZM, mPSL 60 mg/kg | CFPM                                  | Sputum   | TMP-SMX → LVFX due to AKI | Death   | N/A            |
| 3   | Zachary P [21] | Yes                  | Steroid (N/A), DEXA | MEPM                                  | Sputum, blood | TMP-SMX                  | Death   | N/A            |
| 4   | Vikas P [22]   | Yes                  | Tocilizumab, RDV   | N/A                                      | N/A      | N/A                      | N/A     | Cured          |
| 5   | Nicole N [23]  | Yes                  | AZM, HCQ, hydrocortisone 50 mg QID, Tocilizumab | MEPM                                  | Sputum   | LVFX+CAZ                 | Cured   | N/A            |
| 6   | Miraç Öz [24]  | Yes                  | HCQ, AZM, Favipiravir | MEPM                                  | Sputum   | Colistin+FOM             | Cured   | *P. aeruginosa* |
| 7   | David D [25]   | Yes                  | N/A                | N/A                                      | Sputum   | TMP-SMX                  | Cured   | N/A            |
| 8   | Velamakanni S [26] | Yes            | HCQ, Sarilumab     | CTRX                                  | Sputum   | LVFX                     | Cured   | no             |
| 9   | Our case       | Yes                  | RDV, BARI, mPSL (including mPSL pulse) | MEPM                                  | Sputum, blood | TMP-SMX                  | Under treatment | no             |
| 10  | Our case       | Yes                  | RDV, DEXA, AZM     | PIPC/TAZ                              | Sputum   | LVFX                     | Cured   | *K. aerogenes, E. faecalis* |
| 11  | Our case       | Yes                  | RDV, BARI, DEXA    | MEPM                                  | Sputum   | LVFX+MINO due to AKI     | Death   | *Aspergillus sp., Hafnia alvei* |
| 12  | Our case       | Yes/ECMO             | RDV, DEXA, mPSL (including mPSL pulse) | PIPC/TAZ+VCM                       | Sputum   | TMP-SMX                  | Under treatment | *K. aerogenes* |

Contamination
Table 4 continued. Literature review of COVID-19-associated *Stenotrophomonas maltophilia* + cases at our hospital.

| No | Case reference | Mechanical intubation | COVID-19 treatment | Antibiotics prior to *S. maltophilia* infection | Specimen | *S. maltophilia* treatment | Outcome | Other pathogen |
|----|----------------|-----------------------|--------------------|---------------------------------------------|----------|---------------------------|---------|----------------|
| 1  | Our case       | No                    | CTRX, MINO, LPV/RTV| CFPM                                        | Sputum   |                          | Cured   | *E. faecalis*    |
| 2  | Our case       | Post-intubation        | CFPM, MINO, Favipiravir, mPSL | MEPM                                      | Sputum   |                          | Cured   | *E. faecalis, C. albicans* |
| 3  | Our case       | Yes                   | CTRX, favipiravir, mPSL | CAZ+TOB                                   | Blood at autopsy |               | Death   | *P. aeruginosa, A. fumigatus* |
| 4  | Our case       | Yes/ECMO              | CTRX, AZM, RDV, DEXA | PIPC/TAZ+VCM                              | Blood at autopsy |               | Death   | Mold            |

Table 5. List of retrospective cohort studies on *Stenotrophomonas maltophilia* secondary infection to COVID-19.

| No | Study            | Published year/ Country | Ward | number | Site of infection or isolation   | Specimen               | Mortality of respiratory infection | Top 5 pathogen |
|----|------------------|-------------------------|------|--------|---------------------------------|------------------------|-----------------------------------|----------------|
| 1  | Li J [18]        | 2020/ China             | ICU  | *102/110* | *all patients developing secondary bacterial infection * *lung infection | Respiratory infection | *49%* all patients developing secondary bacterial infection | *A. baumannii* 42.7%, *K. pneumoniae* 30.9%, *S. maltophilia* 9.1%, *P. aeruginosa* 6.4%, *E. coli* 3.6% |
| 2  | Foschi C [27]   | 2021/ Italy             | ICU  | *178/230* | *patients developing respiratory infection * *number of lower respiratory samples | Respiratory infection | *N/A*                            | *P. aeruginosa* 14.7%, *K. pneumoniae* 6.9%, *S. aureus* 3.4%, *A. baumannii* 3.4%, *S. maltophilia* 3.4% |
| 3  | Yang S [9]       | 2021/ China             | ICU  | *13/96*  | *critical group patients * number of specimens (BAL, sputum) | Respiratory infection | *N/A*                            | *B. cepacia* 18.8%, *S. maltophilia* 15.6%, *S. aureus* 7.3%, *A. baumannii* 6.3%, *M. morganii* 5.2%, *pathogens detected only in the critical group* |
| 4  | Garcia-Vidal C [28] | 2021/ Spain, non-ICU    | ICU  | *11(VAP), *4(HAP) patients developing S. maltophilia infection | VAP, HAP | *N/A*                        | *VAP* | S. aureus 36.4%, P. aeruginosa 27.3%, S. maltophilia 18.2%, S. marcescens 9% HAP S. aureus 25%, P. aeruginosa 25%, S. maltophilia 25%, K. pneumoniae 25% |
### Table 5 continued. List of retrospective cohort studies on *Stenotrophomonas maltophilia* secondary infection to COVID-19.

| No | Study | Published year/ Country | Ward | number | Site of infection or isolation | Specimen | Mortality of respiratory infection | Top 5 pathogen |
|----|-------|--------------------------|------|--------|--------------------------------|----------|----------------------------------|----------------|
| 5  | Moretti M [29] | 2021/ Belgium | ICU | *21* VAP patients | VAP Endotracheal aspiration BAL | 52.4% (VAP) | K. pneumoniae 25.93%, P. aeruginosa 18.52%, K. oxytoca 11.11%, Enterobacter spp. 11.11%, K. aerogenes 7.41%, 7th S. maltophilia 3.70% |
| 6  | Puzniak L [30] | 2021/ USA | N/A | *5012* all specimens isolation | Urinary, respiratory, blood, skin/wound, intra-abdominal and other specimen | N/A | Enterobacteriaceae 31.8%, S. aureus 13.7%, Enterococcus spp. 7.1%, P. aeruginosa 6.5%, S. pneumoniae 1.9%, S. maltophilia 0.8%, only SARS-CoV-2 positive group |
| 7  | Baiou A [31] | 2021/ Qatar | ICU | *78/98* patients who has isolation of multi-drug-resistant gram-negative bacteria (MDR GNB) **the number of MDR GNB specimens | Respiratory infection, bacteremia, UTI Respiratory tract, blood, urine | 15.4% (all-cause mortality by 28 day) | S. maltophilia 24.25%, K. pneumoniae 23.24%, E. cloacae 18.18%, E. coli 12.12%, S. marcescens 12. 12% |
| 8  | Bardi T [32] | 2021/ Spain | ICU | *57/30* (VAP 21, HAP 9 patients developing nosocomial infection during ICU **number of episodes | VAP, HAP Tracheal aspiration | *36%/37% all-cause mortality by 28 day ** death within all-cause mortality by refractory respiratory failure | VAP P. aeruginosa 38%, MRSA 24%, S. maltophilia 9%, A. baumannii 5%, E. cloacae 5% HAP P. aeruginosa 33%, MRSA 21%, H. influenzae 9%, MSSA 9%, S. maltophilia 9% |
| 9  | Zhang D [33] | 2021/ China | N/A | 23 number of sputum, BAL specimens | Respiratory infection Sputum, BAL | NA | Acinetobacter 26.1%, S. maltophilia 21.7%, K. pneumoniae 13.0%, B. multivorans, R. mannitolyltica, E. cloacae complex 8.7% |
| 10 | Signorini L [10] | 2021/ Italy | ICU | *53/75* patient developing super infection **VAP infection | VAP, HAP BAL | 49.1% (28 day mortality of superinfection) | P. aeruginosa 34.7%, S. maltophilia 18.7% |
in patients with COVID-19. Chest CT imaging abnormalities in COVID-19-associated pneumonia manifest as rapid evolution from focal unilateral to diffuse bilateral ground-glass opacities that progress to or co-exist with consolidations within 1 to 3 weeks [11]. Chest CT imaging abnormalities in *S. maltophilia* infections also appear as ground-glass opacity [12,13], which is difficult to distinguish from that of COVID-19. In the 4 patients in this review, we did not find any new ground-glass opacity when the *S. maltophilia* culture was positive. In these 4 patients, *S. maltophilia* was susceptible to TMP-SMX, LVFX, and MINO. *S. maltophilia* is a multidrug-resistant organism exhibiting intrinsic metallo-beta-lactamases, cephalosporinases, and efflux pumps [14]. Therefore, *S. maltophilia* is resistant to penicillin, cephalosporins, and carbapenems. It is important for the clinician to note that beta-lactams such as carbapenems target extended-spectrum beta-lactamase-producing Enterobacteriaceae and is not effective for *S. maltophilia*. We have to administer TMP-SMX or LVFX to treat *S. maltophilia* infection.

There is limited evidence on effective antimicrobials against *S. maltophilia*. TMP-SMX is the most commonly used drug showing good susceptibility [15]. In the presence of TMP-SMX-induced hypersensitivity reactions and acute kidney injury, LVFX is an alternative; however, 1 study showed no difference in its efficacy compared to that of TMP-SMX [16]. Moreover, LVFX-resistant *S. maltophilia* has emerged worldwide [17]. The aforementioned}

### Table 5 continued. List of retrospective cohort studies on *Stenotrophomonas maltophilia* secondary infection to COVID-19.

| No | Study | Published year/Country | Ward | number | Site of infection or isolation | Specimen | Mortality of respiratory infection | Top 5 pathogen |
|----|-------|------------------------|------|--------|--------------------------------|----------|----------------------------------|----------------|
| 11 | Martinez-Guerra BA [34] | 2021/2022 Mexico ICU, non-ICU | *69/956 new number of specimens of VAP, HAP **number of VAP, HAP episode* | VAP, HAP | N/A | N/A | Enterobacter complex 42.0%, *P. aeruginosa* 14.5%, *Klebsiella* spp. 13.0%, *E. coli* 13.0%, *S. maltophilia* 8.7% |
| 12 | Sang L [35] | 2021/2022 China ICU | 165/935 *number of positive culture patients **number of lower respiratory samples* | HAP, VAP | Lower respiratory tract aspiration | 51.6% at positive culture group (28 days ICU mortality rate) | *K. pneumoniae* 24.6%, *A. baumannii* 24.3%, *S. maltophilia* 11.1%, *P. aeruginosa* 5.7%, *B. cepacia* 4.2% |
| 13 | Luyt C-E [36] | 2020/2021 France ICU | *43 new number of VAP patients* | VAP | BAL | 9% Died on VAP treatment | *P. aeruginosa* 37%, *K. aerogenes* 26%, *E. cloacae* 7%, *Enterococcus* spp. 7%, *Streptococcus* spp. 7%, *MRSA* 5%, *Hafnia alvei* 5%, *S. maltophilia* 5% |

HAP – hospital-acquired pneumonia; VAP – ventilator-associated pneumonia; MOF – multiple organ failure; ARDS – acute respiratory distress syndrome; CAPA – COVID-19 associated pulmonary aspergillosis; AF – atrial fibrillation; HTN – hypertension; CAD – coronary artery disease; DM – diabetes; ESRD – end stage renal disease; TAC – tacrolimus; MMF – mycophenolate mofetil; PSL – prednisolone; BMI – body mass index; COPD – chronic obstructive pulmonary disease; TB – tuberculosis; SLE – systemic lupus erythematosus; RA – rheumatoid arthritis; IP – interstitial pneumonia; LC – liver cirrhosis; BMI – body mass index; COPD – chronic obstructive pulmonary disease; TB – tuberculosis; SLE – systemic lupus erythematosus; RA – rheumatoid arthritis; ICU – Intensive Care Unit; ECMO – extracorporeal membrane oxygenation; N/A – not applicable; HCQ – hydroxychloroquine; AZM – azithromycin; mPSL – methylprednisolone; RDV – remdesivir; DEXA – dexamethasone; QID – quater in die; BARI – baricitinib; CFPM – cefepime; MEPM – meropenem; PIPC/TAZ – piperacillin/tazobactam; VCM – vancomycin; CAZ – ceftazidime; TOB – tobramycin; TMP-SMX – trimethoprim/sulfamethoxazole; LVFX – levofloxacin; MINO – minocycline; AKI – acute kidney injury; FOM – fosfomycin; AKI – acute kidney injury; TMP-SMX is the most commonly used drug showing good susceptibility [15]. In the presence of TMP-SMX-induced hypersensitivity reactions and acute kidney injury, LVFX is an alternative; however, 1 study showed no difference in its efficacy compared to that of TMP-SMX [16]. Moreover, LVFX-resistant *S. maltophilia* has emerged worldwide [17]. The aforementioned

![Image](https://via.placeholder.com/150)

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).

Indexed in: [PMC] [PubMed] [Emerging Sources Citation Index (ESCI)] [Web of Science by Clarivate]

© Am J Case Rep, 2022; 23: e936889
study showed that a history of fluoroquinolone use, previous ICU stay, and the number of previous exposures to different classes of antibiotics were significantly associated with LVFX-resistant S. maltophilia. Another study described the antimicrobial susceptibility of COVID-19-related S. maltophilia [18], and the resistant strains were ceftazidime (90%), LVFX (30%), TMP-SMX (0%), and MINO (0%). In our review, S. maltophilia infection was associated with higher mortality; therefore, we suggest empirically administering TMX-SMP. Further studies are needed to confirm this hypothesis.

This study had some limitations. As VAP and HAP definitions differed among the studies, it was not possible to discern whether S. maltophilia was colonizing or infectious. In addition, no retrospective studies have analyzed the risk factors and mortality associated with S. maltophilia. However, this case review suggested that a history of broad-spectrum antimicrobial use, steroid use, and ICU admission are risk factors for COVID-19-associated S. maltophilia infection.

Conclusions

S. maltophilia is detected in sputum cultures of clinically unstable ICU patients with COVID-19 who are receiving immunosuppressive drugs, are intubated, or are on broad-spectrum antimicrobial agents. We suggest administering treatment for S. maltophilia-associated pneumonia.

Declaration of Figures’ Authenticity

All figures submitted have been created by the authors who confirm that the images are original with no duplication and have not been previously published in whole or in part.

References:

1. Guyot A, Turton JF, Garner D. Outbreak of Stenotrophomonas maltophilia on an Intensive Care Unit. J Hosp Infect. 2013;85:303-7
2. Brooke JS. Stenotrophomonas maltophilia: An emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25:2-41
3. Hotta G, Matsumura Y, Kato K, et al. Risk factors and outcomes of Stenotrophomonas maltophilia bacteraemia: A comparison with bacteraemia caused by Pseudomonas aeruginosa and Acinetobacter species. PLoS One. 2014;9:e112208
4. Imoto W, Yamada K, Yamairi K, et al. Clinical characteristics of rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia. Intern Med. 2020;59:191-98
5. Imoto W, Yamada K, Kuwabara G, et al. In which cases of pneumonia should we consider treatments for Stenotrophomonas maltophilia? J Hosp Infect. 2021;111:169-75
6. Anderson SW, Stapp JR, Burns JI, Qin X. Characterization of small-colony-variant Stenotrophomonas maltophilia isolated from the sputum specimens of five patients with cystic fibrosis. J Clin Microbiol. 2007;45:29-35
7. Irfune K, Ishida T, Shimoguchi K, et al. Pneumonia caused by Stenotrophomonas maltophilia with a mucoid phenotype. J Clin Microbiol 1994;32:2856-57
8. Guerci P, Bellut H, Mokhtari M, et al. Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in Intensive Care Unit: A nationwide retrospective study. Crit Care. 2019;23:371
9. Yang S, Hua M, Liu X, et al. Bacterial and fungal co-infections among COVID-19 patients in Intensive Care Unit. Microbes Infect. 2021;23:104806
10. Signorini L, Moioli G, Calza S, et al. Epidemiological and clinical characterization of superinfections in critically ill coronavirus disease 2019 patients. Crit Care Explor. 2021;3:e00430
11. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis. 2020;20:425-34
12. Kassel TW, Ryan LK, Li A. Computed tomography features of Stenotrophomonas maltophilia pneumonia in patients with neutropenic fever: Report of two cases. cauliflower Respir Med. 2013;8:14
13. Kang YR, Cha YK, Kim JS, et al. Imaging findings of Stenotrophomonas maltophilia pneumonia: emphasis on CT findings between immunocompromised and immunocompetent patients. Acta Radiol. 2020;61:903-9
14. Gil-Gil T, Martinez JL, Blanco P. Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: A review of current knowledge. Expert Rev Anti Infect Ther. 2020;18:335-47
15. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRYS Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents. 2014;43:328-34
16. Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58:176-82
17. Wang C-H, Yu C-M, Hsu S-T, Wu R-X. Levofloxacin-resistant Stenotrophomonas maltophilia: Risk factors and antibiotic susceptibility patterns in hospitalized patients. J Hosp Infect. 2020;104:46-52
18. Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: A retrospective analysis. Antimicrob Resist Infect Control. 2020;9:153
19. Su XW, Palka SV, Rao RR, et al. SARS-CoV-2-associated Guillain-Barre syndrome with dysautonomia. Muscle Nerve 2020;62:E48-49
20. Mohamed MA, Kaur J, Wani F, Kichloo A, Bhanot R. Renal transplant recipient with concurrent COVID-19 and Stenotrophomonas maltophilia pneumonia treated with trimethoprim/sulfamethoxazole leading to acute kidney injury: A therapeutic dilemma. Am J Case Rep 2020;21:e296464
21. Pek Z, Cabañilla MG, Ahmed S. Treatment refractory Stenotrophomonas maltophilia bacteraemia and pneumonia in a COVID-19-positive patient. BMJ Case Rep 2021;14:e246270
22. Pothak V, Waltje J, Chalise SN. Use of endobronchial valve to treat COVID-19 adult respiratory distress syndrome-related alveoloepithelial fistula. Lung India 2021;38:569-71
23. Nourié N, Chamaa MA, Mouawad S, et al. Effective treatment with Tobacmana a COVID-19 patient on maintenance hemodialysis: A case report. CEN Case Rep 2021;10:364-69
24. Öz M, Kaya AG, Yakut ÖV, et al. Successful treatment of COVID-19 infection in a patient with tracheostomy. Turk Tab Kas 2020;68:444-48
25. Davishnia D, Sadeghi M, Sharifpour A, et al. Co-morbidity of COVID-19 and Stenotrophomonas maltophilia in a patient with Hodgkin’s lymphoma history from north of Iran. Infect Disord Drug Targets. 2021;21:e1609211124
26. Abstracts from the 2021 Annual Meeting of the Society of General Internal Medicine. J Gen Intern Med 2021;36:469
27. Foschi C, Zignoli A, Gaibani P, et al. Respiratory bacterial co-infections in Intensive Care Unit-hospitalized COVID-19 patients: Conventional culture vs BioFire FilmArray pneumonia Plus panel. J Microbiol Methods 2021;186:106259
28. García-Vidal C, Sanjuán G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study. Clin Microbiol Infect. 2021;27:83-88
29. Moretti M, Van Laethem J, Minini A, et al. Ventilator-associated bacterial pneumonia in coronavirus 2019 disease, a retrospective monocentric cohort study. J Infect Chemother 2021;27:826-33
30. Puzniak L, Finelli L, Yu KC, et al. A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19. BMC Infect Dis 2021;21:227
31. Baiou A, Elbuzidi AA, Bakdach D, et al. Clinical characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative bacteria from critically ill patients with COVID-19. J Hosp Infect 2021;110:165-71
32. Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, et al. Nosocomial infections associated to COVID-19 in the Intensive Care Unit: Clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis 2021;40:495-502
33. Zhang H, Zhang Y, Wu J, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect 2020;9:1958-64
34. Martinez-Guerra BA, Gonzalez-Lara MF, de-Leon-Cividanes NA, et al. Antimicrobial resistance patterns and antibiotic use during hospital conversion in the COVID-19 pandemic. Antibiotics (Basel) 2021;10:182
35. Sang L, Xi Y, Lin Z, et al. Secondary infection in severe and critical COVID-19 patients in China: a multicenter retrospective study. Ann Palliat Med 2021;10:8557-70
36. Luyt C-E, Sahnoun T, Gautier M, et al., Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: A retrospective cohort study. Ann Intensive Care. 2020.10:158